Lopinavir/ritonavir population pharmacokinetics in neonates and infants

British Journal of Clinical Pharmacology

Volumn 71, Issue 6, 2011, Pages 956-960

  Urien, Saik ^a,b,c   Firtion, Ghislaine ^d   Anderson, Suzanne T ^e,j   Hirt, Deborah ^a,b,c   Solas, Caroline ^g   Peytavin, Gilles ^h   Faye, Albert ⁱ   Thuret, Isabelle ^g   Leprevost, Marthe ^f   Giraud, Carole ^a,b,c   Lyall, Hermione ^j   Khoo, Saye ^k   Blanche, Stéphane ^a,c,l   Tréluyer, Jean Marc ^a,b,c,d  

^a Université Paris Descartes   (France)

^b HÔPITAL SAINT VINCENT DE PAUL   (France)

^c INSERM   (France)

^d Brighton and Sussex Medical School ^*  (France)

^e BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^f NORTHWICK PARK HOSPITAL   (United Kingdom)

^g TIMONE HOSPITAL   (France)

^h BICHAT HOSPITAL   (France)

ⁱ HÔPITAL ROBERT DEBRÉ   (France)

^j IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^k UNIVERSITY OF LIVERPOOL   (United Kingdom)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

Children; Lopinavir ritonavir; Neonates; Population pharmacokinetics

Indexed keywords

LOPINAVIR PLUS RITONAVIR;

ADULT; ALLOMETRY; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MENSTRUATION; NEWBORN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL;

ANTI-HIV AGENTS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; INFANT; INFANT, NEWBORN; LOPINAVIR; MALE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR;

EID: 79955824882     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03926.x     Document Type: Article

References (9)

1. Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH, Chen J, Palumbo P, Serchuck L, Smith E, Hughes M. Pharmacokinetics, safety and efficacy of Lopinavir/ritonavir in infants less than 6 months of age: 24 weeks results. AIDS 2008; 22: 249-55.
2. Verweel G, Burger DM, Sheehan NL, Bergshoeff AS, Warris A, van der Knaap LC, Driessen G, de Groot R, Hartwig NG. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below. Antivir Ther 2007; 12: 453-8.
3. Crommentuyn KM, Kappelhoff BS, Mulder JW, Mairuhu AT, van Gorp EC, Meenhorst PL, Huitema AD, Beijnen JH. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2005; 60: 378-89.
4. Jullien V, Urien S, Hirt D, Delaugerre C, Rey E, Teglas JP, Vaz P, Rouzioux C, Chaix ML, Macassa E, Firtion G, Pons G, Blanche S, Treluyer JM. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother 2006; 50: 3548-55.
5. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247: 625-34.
6. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 2005; 49: 1020-30.
7. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32.
8. Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods 2008; 90: 154-66.
9. Ihaka R, Gentleman RR. A language for data analysis and graphics. J Comput Graphic Stat 1996; 5: 299-314.